race oncology ltd advances zantrene aml trials
Published 2 years ago • 1.2K plays • Length 5:40Download video MP4
Download video MP3
Similar videos
-
6:49
race oncology receives positive results from aml trial of bisantrene
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
5:00
race oncology secures governance approval for open-label zantrene trial
-
6:42
race oncology looks to accelerate clinical development of bisantrene
-
4:41
acute myeloid leukemia survival rate and outlook
-
3:15
what is leukemia?
-
5:33
leukemia, causes, signs and symptoms, diagnosis and treatment.
-
5:40
race oncology discusses clinical progress and march quarter highlights
-
20:31
race oncology (asx: rac) – zantrene’s role as an fto inhibitor to cure cancer globally
-
5:13
are clinical trials an option in treatment failure or relapse in aml?
-
3:50
race oncology expands vision beyond cancer with new drug discovery program
-
38:32
investor presentation
-
2:32
how quickly does aml progress? #aml
-
27:35
race oncology (asx: rac) – breakthrough cancer treatment discovery
-
3:11
how can i choose a clinical trial for aml?
-
0:59
dr. mesa on racial disparities in mpn, mds, and aml clinical trials
-
54:22
race oncology (asx:rac) investor briefing - melbourne 20th oct 2022
-
45:09
race oncology june 2022 quarterly investor briefing
-
2:33
upcoming clinical trials for venetoclax chemotherapy combinations for aml
-
1:37
a phase ii trial evaluating e7820 in patients with aml with splicing factor mutations
-
1:26
understanding high risk acute myeloid leukemia treatment advances and options